Labrousse C L, Munoz M, Kramer F
CHRU Limoges, Frante.
Scand J Rheumatol Suppl. 1989;80:62-6. doi: 10.3109/03009748909103715.
The effectiveness and tolerability of tenoxicam and piroxicam, administered as a once-daily 20 mg suppository, were assessed in a comparative, randomised, double-blind trial in 48 subjects suffering from acute non-articular rheumatism. Both spontaneous and induced pain improved significantly with each of the treatments. There was no significant difference between the two treatments, whatever criterion of effectiveness was considered, i.e. spontaneous pain, induced pain or overall judgement. The incidence of undesirable side-effects was comparable for both treatments. Thirteen per cent of patients in the tenoxicam group and 16% of the patients in the piroxicam group experienced at least one undesirable side-effect. The majority of reported side-effects were of a digestive nature; however none of these were serious. The risk/benefit ratio of tenoxicam was found to be identical to that of piroxicam in the treatment of acute non-articular rheumatism.
在一项针对48名急性非关节性风湿病患者的比较、随机、双盲试验中，评估了替诺昔康和吡罗昔康以每日一次20毫克栓剂给药的有效性和耐受性。两种治疗方法均使自发痛和诱发性疼痛显著改善。无论采用何种有效性标准，即自发痛、诱发性疼痛或总体判断，两种治疗方法之间均无显著差异。两种治疗方法的不良副作用发生率相当。替诺昔康组13%的患者和吡罗昔康组16%的患者至少经历了一种不良副作用。报告的副作用大多为消化系统性质；然而，这些副作用均不严重。在治疗急性非关节性风湿病方面，发现替诺昔康的风险/效益比与吡罗昔康相同。
